Mon panier

ENPP3

ENPP3 Informations sur la molécule

Nom anglaisEctonucleotide pyrophosphatase/phosphodiesterase family member 3Nombre de médicaments commercialisés0
Nombre de médicaments cliniques4Alias de la cibleEC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Phase de R&D la plus avancéePhase 1 Clinical
Nom anglaisEctonucleotide pyrophosphatase/phosphodiesterase family member 3
Alias de la cibleEC:3.1.4.1,E-NPP 3,PD-Ibeta,NPPase,CD203c,PDNP3,Phosphodiesterase I/nucleotide pyrophosphatase 3,Nucleotide diphosphatase,ENPP3,DJ914N13.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),Phosphodiesterase-I Beta,Phosphodiesterase I Beta,CD203c Antigen,Gp130RB13-6,NPP3,B10,Ectonucleotide pyrophosphatase/phosphodiesterase family member 3,Ectonucleotide Pyrophosphatase/Phosphodiesterase 3,DJ1005H11.3 (Phosphodiesterase I/Nucleotide Pyrophosphatase 3),EC:3.6.1.9
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques4
Phase de R&D la plus avancéePhase 1 Clinical

ENPP3Contexte de la molécule

The human NPP family contains seven members which can be classified into two groups according to their substrate preferences. The first class comprises the nucleotide-degrading proteins NPP1, 3 and 4. NPP3 (CD203c, ENPP3) is expressed in multiple organs, including on epithelial and mucosal surfaces, and notably on basophils and mast cells. Activation of basophils by antigen-bound IgE leads to release of inflammatory mediators and rapid upregulation of NPP3 to the cell surface. This protein is in fact a common marker for diagnosing allergen sensitivity with patient basophils by flow cytometry. Basophils and mast cells mediate the response to certain pathogens, as well as acute and chronic allergic reactions. Following activation, these cells release ATP, which further stimulates them in an autocrine manner. NPP3 upregulation serves to degrade ATP and suppress chronic allergic inflammation (but not the acute response).

ENPP3Alias de la molécule

ENPP3,CD203c,NPP3,E-NPP3,PD-Ibeta,NPPase,PDNP3

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
XmAb-819XmAb-819Phase 1 ClinicalXencor IncCarcinoma, Renal Cell; Kidney Neoplasms
Details
JNJ-89862175JNJ-89862175Phase 1 ClinicalJanssen Research & Development LlcSolid tumours
Details
ALY-301ALY-301; GTX-B001Phase 1 ClinicalAlys Pharmaceuticals IncChronic Urticaria; Symptomatic Dermographism; Urticaria
Details
JNJ-87890387JNJ-87890387Phase 1 ClinicalJanssen Research & Development LlcNeoplasms; Solid tumours
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques